Monte Rosa Therapeutics, Inc.
GLUE
$18.15
-$0.53-2.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -73.07% | 63.54% | 1,112.27% | 2,990.57% | 14,889.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -73.07% | 63.54% | 1,112.27% | 2,990.57% | 14,889.38% |
| Cost of Revenue | 23.17% | 18.46% | 28.55% | 18.61% | 53.89% |
| Gross Profit | -347.32% | 73.07% | 158.86% | 158.53% | 154.76% |
| SG&A Expenses | 5.19% | 0.70% | 0.17% | -2.82% | 10.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.32% | 13.49% | 20.20% | 12.29% | 11.41% |
| Operating Income | -6,864.68% | 33.17% | 106.60% | 110.73% | 98.52% |
| Income Before Tax | -1,493.80% | 43.36% | 118.45% | 121.88% | 107.02% |
| Income Tax Expenses | -156.42% | -142.68% | 162.50% | 781.16% | 685.99% |
| Earnings from Continuing Operations | -2,213.02% | 46.87% | 117.54% | 118.53% | 104.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2,213.02% | 46.87% | 117.54% | 118.53% | 104.55% |
| EBIT | -6,864.68% | 33.17% | 106.60% | 110.73% | 98.52% |
| EBITDA | -2,378.06% | 37.18% | 113.91% | 117.68% | 104.48% |
| EPS Basic | -8,273.74% | 58.78% | 113.97% | 113.11% | 100.71% |
| Normalized Basic EPS | -2,665.19% | 56.20% | 114.65% | 115.44% | 102.30% |
| EPS Diluted | -11,854.40% | 58.74% | 113.80% | 113.02% | 100.49% |
| Normalized Diluted EPS | -2,939.76% | 55.67% | 114.35% | 115.19% | 102.08% |
| Average Basic Shares Outstanding | 10.24% | 12.44% | 21.65% | 37.93% | 46.77% |
| Average Diluted Shares Outstanding | 9.96% | 12.71% | 21.95% | 38.27% | 47.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |